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Antithrombin Glasgow is a hereditary abnormal antithrombin that has lost thrombin inhibitory activity. It was isolated 
from the plasma of a 41-year-old male with a history of thrombotic events. Antithrombin Glasgow was purified from 
plasma using heparin-Sepharose chromatography at pH 7.4 eluting with increasing concentrations of NaCl. The normal 
protein eluted with 0.9 mol/l NaCl and Glasgow with 1.05 mol/l NaCI. Electrophoresis in agarose at pH 8.6 showed 
the variant to migrate more anodally than normal. The C-terminal small fragment resulting from catalytic cleavage with 
elastase between P, and P4 of the reactive loop was isolated and sequenced. This showed the replacement of the arginine 
at residue 3 by a histidine. This is residue 393 in the intact molecule. The findings suggest that heparin, on binding, inter- 
acts indirectly with the reactive centre region of antithrombin. 
Antithrombin; Pathological variant; Heparin binding; Reactive site mutant 
1. INTRODUCTION 
Antithrombin (AT) is the major physiological 
inhibitor of thrombin. The rate of inhibition of its 
target enzymes is greatly increased through interac- 
tion with heparin [l]. A syndrome of recurrent 
thrombosis was reported by Egeberg in 1965 [2] to 
be related to a deficiency of AT. Since then, there 
have been many reports of quantitative deficien- 
cies and an increasing number of reports of 
qualitative abnormalities of AT. 
The molecular characterisation of these variants 
has revealed that the substitutions involve two ma- 
jor areas on the molecule: the N-terminal heparin 
binding region with substitutions at residues 47 
and 41 accounting for four characterised variants 
[3-71 and the other region being the reactive centre 
with variants, such as AT Denver, residue 394 [8] 
and Hamilton, residue 382 [9]. The precise loca- 
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tion of the areas of interaction between heparin 
and antithrombin and details of the resultant 
mechanism of activation are as yet unclear. 
We report here a new variant of antithrombin 
where the Pr reactive centre arginine residue has 
been replaced by a histidine. This has, somewhat 
surprisingly, resulted in an increase in heparin af- 
finity. The mutant has lost both progressive and 
heparin cofactor activity. 
2. MATERIALS AND METHODS 
2.1. Antithrombin assays 
The plasma concentration of immunoreactive antithrombin 
was determined by Laurel1 rockets [IO]. Functional studies were 
performed with and without heparin using the chromogenic 
substrate Chromozym-TH for thrombin [5]. 
2.2. Isolation of antithrombin 
Antithrombin was isolated from plasma on heparin- 
Sepharose [ll]. To 100 ml of plasma was added 1 ml each of 
5 mol/l calcium chloride and 10% dextran sulphate (Mr 
500000) solution. The supernatant was loaded onto the heparin- 
Sepharose column (2.5 x 30 cm) equilibrated with 0.05 mol/l 
Tris, 0.01 mol/l citrate, 0.1 mol/l NaCI, pH 7.4. The an- 
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tithrombins were eluted with a linear NaCl gradient to 
1.5 mol/l. 
2.3. Heparin binding at pH 6.0 
The supernatant from plasma treated, as above, with calcium 
chloride and dextran sulphate was adjusted to pH 6.0 with HCl 
and loaded onto a heparin-Sepharose column equilibrated with 
0.01 mol/l sodium citrate, 0.01 mol/l disodium EDTA, pH 6.0. 
The bound antithrombins were eluted with a linear NaCl gra- 
dient to 1.5 mol/l. 
2.4. Complex formation with thrombin 
A fixed amount (25 pg) of AT, dissolved in 10 ~1 of barbitol 
buffer, pH 8.3, was allowed to react in the presence of 1 unit 
of heparin with varying amounts (1.0, 2.5, 5.0, 12.5 pg) of 
bovine thrombin for 10 min at 25°C. These were then run on 
a reduced 10% SDS-polyacrylamide gel. 
2.5. Electrophoresis on agarose and sodium dodeeyl sulphate 
polyacrylamide gels 
Electrophoresis was carried out on 1% agarose at pH 8.6 in 
0.075 mol/l barbital buffer [12]. M, values were determined 
from electrophoretic mobilities in 10% SDS-polyacrylamide 
gels according to the method of Laemmli [13]. 
2.6. Catalytic cleavage with elastase and isolation of small 
fragment 
AT was catalytically cleaved with elastase [14], and the 
fragments separated by ethanol precipitation [ 151. Purified an- 
tithrombin, 1 mg, was dissolved in 200~1 of phosphate buf- 
fered saline to which was added 500 IU of heparin (mucous, 
Evans Medical, Liverpool, England) and 1Opg of human 
neutrophil elastase (gift from Dr C.C. Winterbourn). This was 
incubated at 37°C for 40 min, taking 2 pl aliquots to monitor 
thrombin inhibitory activity at IO min intervals. The sample 
was then concentrated and dialysed against distilled water using 
an Amicon stirred concentrating cell. The sample was im- 
mediately frozen (volume about 200~1) and 30 mg of sodium 
dodecyl sulphate, and 50 pl of mercaptoethanol were added and 
immediately heated in a boiling water bath for 10 min. The 
large fragment was precipitated by adding 5 vols of ethanol and 
the supernatant was dried down under NZ and redissolved in 
300 pl of water. This was then added dropwise to 4 ml of 1 Vo 
HCI in acetone while vortex mixing. The supernatant was 
discarded and the small fragment dried under Nz. 
2.7. Amino acid sequencing 
The manual Edman degradation method was used. The PTH- 
amino acids were identified by reverse-phase HPLC using a 
Waters Nova pat column. 
2.8. Case report 
A 41-year-old man with a history of spontaneous venous 
thromboembolism underwent laboratory studies for coagula- 
tion abnormalities. These showed his antithrombin activity in 
the presence of heparin to be 52% of a normal pool. Both his 
sisters showed low antithrombin functional activity, and had 
suffered thrombotic events. His three brothers also had low 
functional activity with one suffering from deep venous throm- 
bosis. The propositus’ father died (aged 47 yr) from a coronary 
thrombosis as did one of the father’s two brothers (at age 
318 
31 yr). All three of the propositus’ children have low heparin 
cofactor activity. 
3. RESULTS 
The antigenic level of antithrombin in the pro- 
positus’ plasma was 96% of a normal pool whereas 
the thrombin inhibitory activity in the presence of 
heparin was 52% of a normal pool. 
Chromatography of the patient’s plasma on 
heparin-Sepharose at pH 7.4 showed the presence 
of an antithrombin of increased heparin affinity 
(fig. 1). Normal antithrombin eluted with 0.9 mol/l 
of NaCl whereas antithrombin Glasgow eluted 
with 1.05 mol/l NaCl. At pH 6.0 normal AT and 
AT Glasgow coeluted from heparin-Sepharose at 
1.05 mol/l NaCI. 
The M, values of the proteins were identical at 
58000. Electrophoresis on agarose gel showed an- 
tithrombin Glasgow to migrate more anodally than 
the normal at pH 8.6 (fig.2). Immunofixation with 
antiserum to antithrombin following elec- 
trophoresis at pH 8.6 of plasma from the pro- 
positus showed two bands, confirming that the 
abnormal band had not arisen as an artifact during 
purification (fig.2). 
Normal AT reacted with thrombin to form a 
complex with a band at Mr 83000 and a minor 
band at M, 92000 (fig.3). With increasing amounts 
of thrombin there was a further band at M, 78000, 
which is presumably a degradation product of the 
complex. In contrast the abnormal AT did not 
react with thrombin to form a complex (fig.3). 
Following catalytic cleavage by elastase both the 
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Fig. 1. Elution profile of heparin-Sepharose chromatography of 
patient’s plasma at pH 7.4 with increasing linear NaCl gradient. 
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Fig.2. Electrophoresis in agarose gel at pH 8.6 of normal 
human serum (a), purified normal antithrombin (AT) (b), and 
purified AT Glasgow (c). The results of immunofixation with 
antiserum to AT following electrophoresis are shown of the 
patient’s plasma (d) and normal plasma (e). 
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Fig.3. SDS-polyacrylamide gel of normal AT (a) and AT 
Glasgow (b). Lanes c-f show the result of incubation of 
increasing amounts of thrombin with normal AT, and lanes g-j 
with AT Glasgow. Track k has bovine thrombin. The gel was 
run under reducing conditions. 
large fragment (that precipitated on addition of 
5 vols of ethanol), and the small fragment were se- 
quenced for 5 residues on both the normal and ab- 
normal proteins. The sequences obtained for the 
large fragment from both normal and Glasgow 
were identical, His-Gly-Ser-Pro-Val, and corres- 
pond to the N-terminal of the intact protein. The 
first residues of the small fragment from Glasgow 
had the sequence Ala-Gly-His-Ser-Leu. This dif- 
fered from that obtained from the normal small 
fragment at residue 3 which had the expected 
arginine. This corresponds to residue 393, the Pi 
position, in the intact protein. 
4. DISCUSSION 
We report here a new variant of antithrombin, 
antithrombin Glasgow, that has increased heparin 
binding but has lost thrombin inhibitory activity. 
This has arisen from the replacement of the normal 
Pi reactive site arginine (residue 393) by a his- 
tidine. Somewhat surprisingly this binds heparin 
more avidly. The majority of variants with altered 
heparin binding affinity have involved a region in 
the vicinity of the start of helix A [5] with arginine 
at residue 47 being replaced by cysteine [3,4], 
histidine [.5] and serine [6], and the proline at 41 
being replaced by leucine [7]. All these variants 
bind heparin less avidly than normal. The 
mechanism of heparin interaction and activation 
of antithrombin is not clear. We have shown that 
it is unlikely to involve a direct shielding of the ac- 
tive site by the N-terminal tail [5], and have sug- 
gested a positively charged groove comprising 
residues 47, 125, 129, 132 and 133 to be the likely 
site of heparin binding [ 161. On charge considera- 
tions alone, it would be expected that the replace- 
ment of the positively charged arginine residue at 
the Pr position by a histidine that would be un- 
charged at pH 7.4 [17] should, if there were direct 
interaction with heparin, result in a decrease in 
heparin affinity. However, the reverse occurs. Pro- 
tonation of the new Pr histidine by reducing the 
pH to 6.0 results in a return to normal heparin 
binding. This is in contrast to AT Rouen-I (47 Arg 
to His) where protonation of the new histidine did 
not restore the variant to normal heparin affinity 
[5]. This implies that the Pr arginine is involved in 
an indirect manner in heparin binding; presumably 
319 
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by a salt bridge to some other region of the 
molecule. Loss of the positive charge at the Pi 
residue results in an altered conformation which is 
more favourable for heparin binding. This is also 
seen with AT Northwick Park where there is a 
substitution of the Pi arginine for a non-charged 
cysteine residue [18]. In contrast to the N-terminal 
variants which are activated on binding to heparin, 
the Glasgow variant although it binds more avidly 
than normal is not activated by heparin. In this 
case binding per se is not a sufficient condition for 
activation. 
In the serpins the Pi residue is one of the prime 
determinants of inhibitor specificity [ 191. 
Antitrypsin-Pittsburgh is an example of a dramatic 
alteration of specificity resulting from the substitu- 
tion of the residue [20]. Replacing the Pi 
methionine by arginine converted antitrypsin- 
Pittsburgh from an elastase inhibitor to a potent 
inhibitor of thrombin. AT Glasgow, as a result of 
the replacement of the important Pi arginine by 
histidine has lost the ability to inhibit thrombin. 
We were unable to show the formation of a com- 
plex with thrombin. This is not surprising since the 
only serpin reported to date with a histidine at the 
Pi residue is the chicken gene-Y protein which has 
no reported inhibitory activity [21,22]. 
The thrombotic episodes suffered by the pro- 
positus are related to the presence of this variant of 
antithrombin. Not only is AT Glasgow not ac- 
tivated by heparin but the fact that it binds heparin 
more avidly than normal means that, at sub- 
optimal levels of heparin, the heparin will 
preferentially bind the variant with no resultant in- 
crease in plasma antithrombin activity. These two 
factors, the loss of heparin cofactor activity and 
the increased avidity for heparin, combine to pro- 
duce a situation that is potentially more serious 
than the heterozygous quantitative deficiency 
state. 
It was our initial intention to call this variant AT 
Waikato. It has come to our attention that a cousin 
of the propositus has been independently in- 
vestigated by Lane et al. [18] who have named the 
variant AT Glasgow. Because of their prior 
publication [23], and to avoid confusion in the 
literature we accept the name AT Glasgow. 
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